NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/15/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,248.93 mln
Float88.05 mln
Earnings Date08/11/2026
Piotroski F-Score
3
/ 9
Below average
Beneish M-Score
-0.5
Highly suspicious
1-Year Forecast
51.13
Transformational upside
Relative Strength
9
/ 100
Severely lagging
Debt / Equity
0.22
Very low leverage
ROE
-5.87
Negative
Business Description
Beam Therapeutics is a Cambridge, Massachusetts-based biotech company founded in 2017 that develops targeted gene-editing treatments for patients with serious inherited conditions. The company is advancing a pipeline of therapies for blood disorders and genetic diseases, including treatments for sickle cell disease, alpha-1 antitrypsin deficiency, and several rare liver conditions. Beam also works with partners such as Pfizer, Verve Therapeutics, and Orbital Therapeutics to expand its gene-editing research across the liver, muscle, and nervous system.
